<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860171</url>
  </required_header>
  <id_info>
    <org_study_id>2238.00</org_study_id>
    <secondary_id>NCI-2010-00128</secondary_id>
    <secondary_id>2238.00</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00860171</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody
      BC8 when given before autologous stem cell transplant in treating patients with Hodgkin
      lymphoma or non-Hodgkin lymphoma that has returned after a period of improvement or does not
      respond to treatment. Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal
      antibody BC8, can find cancer cells and carry cancer-killing substances to them without
      harming normal cells. Giving iodine I 131 monoclonal antibody BC8 before an autologous stem
      cell transplant may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the maximally tolerated dose of 131I-BC8 (anti-cluster of differentiation
      [CD]45) (iodine I 131 monoclonal antibody BC8) that can be delivered prior to autologous stem
      cell transplantation for patients with relapsed/refractory B-non-Hodgkin lymphoma (NHL),
      T-NHL, or Hodgkin lymphoma (HL).

      SECONDARY OBJECTIVES:

      I. To optimize the protein dose (antibody [Ab]) to deliver a favorable biodistribution in the
      majority of patients.

      II. To assess the radiation dose delivered to tumor sites and normal organs by the above
      therapy.

      III. To evaluate the dose-response relationship of radiation-dose to tumor and clinical
      response.

      IV. To estimate the overall and progression-free survival of the above regimen in such
      patients.

      V. To evaluate the toxicity and tolerability of the above therapy.

      VI. To evaluate the feasibility of delivering high-dose 131I-BC8 and autologous stem cell
      transplantation (ASCT) to B-Cell NHL, T-NHL, and HL patients.

      VII. To evaluate the ability to reduce infusion reactions via unlabeled BC8 preinfusion.

      OUTLINE: This is a dose-escalation study.

      Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 intravenously (IV)
      on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to
      2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2
      weeks apart. Patients then undergo autologous stem cell transplantation on day 0.

      After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months and
      then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single site, open label clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of I-131-BC8 That Can be Delivered Prior to Transplant</measure>
    <time_frame>Within 30 days post-transplant</time_frame>
    <description>Dose escalation/de-escalation will be conducted by the &quot;two-stage&quot; approach introduced by Storer. Escalation will continue until a dose-limiting toxicity (DLT) occurs. A DLT will be defined as a therapy-related grade III or IV Bearman (transplant) toxicity. The MTD is estimated to be the dose that is associated with a toxicity rate of 25% (Bearman grade 3-4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>I-131 Activity Administered</measure>
    <time_frame>At time of I-131 therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Descriptive statistics will be calculated. DLT will be defined by the Bearman Scale that is designed to address the specific toxicities associated with transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Kaplan-Meier estimates will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Summarized using cumulative incidence estimates combining all patients and will be utilized as a rough guide to the potential benefits and toxicities of this therapy, but no formal statistical comparisons with regard to efficacy will be made because of the phase I nature of this trial.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <condition>Refractory T-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (iodine I 131 monoclonal antibody B, autologous HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Autologous stem cells given via central catheter</description>
    <arm_group_label>Treatment (iodine I 131 monoclonal antibody B, autologous HCT)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Iodine I 131 Monoclonal Antibody BC8</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (iodine I 131 monoclonal antibody B, autologous HCT)</arm_group_label>
    <other_name>I 131 MOAB BC8</other_name>
    <other_name>I 131 Monoclonal Antibody BC8</other_name>
    <other_name>iodine I 131 MOAB BC8</other_name>
    <other_name>MOAB BC8, iodine I 131</other_name>
    <other_name>monoclonal antibody BC8, iodine I 131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (iodine I 131 monoclonal antibody B, autologous HCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of B-NHL, T-NHL, or HL; CD45
             antigen expression must be documented on tumor specimens in all cases except HL, in
             whom histologic demonstration of CD45+ cells adjacent to the Reed Sternberg cells is
             required

          -  Patients must have received at least one prior standard systemic therapy with
             documented recurrent or refractory disease

          -  Mantle cell lymphoma (MCL), T-NHL, or other high-risk malignancies may be
             enrolled/transplanted in complete remission (CR)/first partial remission (PR1)

          -  Patients are preferred to have either a tumor mass amenable to core needle biopsy
             during the dosimetry phase, or a measurable tumor mass with at least one site of
             involvement measuring 2.0 cm in largest dimension on computed tomography (CT) imaging
             for purposes of planar and/or single-photon emission CT (SPECT)/CT tumor dosimetry
             (patients with disease that does not allow tumor dosimetry will be allowed on study
             since they still can contribute toward achieving the primary endpoint, but these
             patients will be given a lower priority over those with evaluable disease)

          -  Creatinine [Cr] &lt; 2.0

          -  Bilirubin &lt; 1.5 mg/dL, with the exception of patients thought to have Gilbert's
             syndrome, who may have a total bilirubin above 1.5 mg/dL

          -  All patients eligible for therapeutic study must have a minimum of &gt;= 4 x10^6 CD34/kg
             autologous hematopoietic stem cells harvested and cryopreserved and divided into 2
             aliquots of at least &gt;= 2 x10^6 CD34/kg each; patients with a history of prior
             autologous hematopoietic cell transplant (HCT) are only required to have &gt;= 2x10^6
             CD34/kg stored

          -  Patients must have an expected survival of &gt; 60 days and must be free of major
             infection

        Exclusion Criteria:

          -  Circulating human anti-mouse antibody (HAMA), to be determined before each infusion

          -  Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled
             therapy dose with the exception of rituximab

          -  Inability to understand or give an informed consent

          -  Lymphoma involving the central nervous system

          -  Other serious medical conditions considered to represent contraindications to bone
             marrow transplant (BMT) (e.g. abnormally decreased cardiac ejection fraction,
             diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 50% predicted, forced
             expiratory volume in one second (FEV1) &lt; 70% predicted, acquired immune deficiency
             syndrome [AIDS], etc.)

          -  Known human immunodeficiency virus (HIV) seropositivity

          -  Pregnancy or breast feeding

          -  Prior allogeneic bone marrow or stem cell transplant

          -  Prior autologous bone marrow or stem cell transplant or prior radiation therapy (RT) &gt;
             20 Gy to a critical organ within 1 year of enrollment

          -  Presence of circulating lymphoma cells by morphology or flow cytometry (&gt; 0.1%) at or
             near the time of peripheral blood stem cell (PBSC) collection if unpurged/unselected
             PBSC are to be used (patients with cryopreserved stem cells which are negative [=&lt;
             0.1% involved] by flow cytometry will also be considered eligible)

          -  Southwest Oncology Group (SWOG) performance status &gt;= 2.0

          -  Unable to perform self-care during radiation isolation

          -  Expected survival if untreated less than 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <results_first_submitted>October 7, 2016</results_first_submitted>
  <results_first_submitted_qc>October 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2017</results_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
          <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
          <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.81" spread="15.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of I-131-BC8 That Can be Delivered Prior to Transplant</title>
        <description>Dose escalation/de-escalation will be conducted by the &quot;two-stage&quot; approach introduced by Storer. Escalation will continue until a dose-limiting toxicity (DLT) occurs. A DLT will be defined as a therapy-related grade III or IV Bearman (transplant) toxicity. The MTD is estimated to be the dose that is associated with a toxicity rate of 25% (Bearman grade 3-4).</description>
        <time_frame>Within 30 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
            <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of I-131-BC8 That Can be Delivered Prior to Transplant</title>
          <description>Dose escalation/de-escalation will be conducted by the &quot;two-stage&quot; approach introduced by Storer. Escalation will continue until a dose-limiting toxicity (DLT) occurs. A DLT will be defined as a therapy-related grade III or IV Bearman (transplant) toxicity. The MTD is estimated to be the dose that is associated with a toxicity rate of 25% (Bearman grade 3-4).</description>
          <units>Gray of I-131 (absorbed dose that the I</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No dose-limiting toxicities observed. Funding ran out, and no MTD identified by the time last patient treated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>I-131 Activity Administered</title>
        <time_frame>At time of I-131 therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
            <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>I-131 Activity Administered</title>
          <units>mCi I-131</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668.15" lower_limit="344" upper_limit="1064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Descriptive statistics will be calculated. DLT will be defined by the Bearman Scale that is designed to address the specific toxicities associated with transplantation.</description>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
            <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Descriptive statistics will be calculated. DLT will be defined by the Bearman Scale that is designed to address the specific toxicities associated with transplantation.</description>
          <units>number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
            <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1057" spread="633.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Kaplan-Meier estimates will be calculated.</description>
        <time_frame>Up to 6 years</time_frame>
        <posting_date>12/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Rate</title>
        <description>Summarized using cumulative incidence estimates combining all patients and will be utilized as a rough guide to the potential benefits and toxicities of this therapy, but no formal statistical comparisons with regard to efficacy will be made because of the phase I nature of this trial.</description>
        <time_frame>Up to 6 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Iodine I 131 Monoclonal Antibody B, Autologous HCT)</title>
          <description>Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
Autologous Hematopoietic Stem Cell Transplantation: Autologous stem cells given via central catheter
Iodine I 131 Monoclonal Antibody BC8: Given IV
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>non-neutropenic fever</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This protocol was closed to enrollment when replaced by a newer approach.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ajay K. Gopal, MD</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-288-2037</phone>
      <email>agopal@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

